Hemoglobin-Based Oxygen Carriers: Potential Applications in Solid Organ Preservation

Min Cao¹, Guoqing Wang¹, Hongli He¹, Ruiming Yue¹, Yong Zhao², Lingai Pan¹, Weiwei Huang¹, Yang Guo¹, Tao Yin³, Lina Ma⁴, Dingding Zhang⁵* and Xiaobo Huang¹*

¹Department of Critical Care Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China, ²Anesthesiology, Southwest Medicine University, Luzhou, China, ³Surgical Department, Chengdu Second People’s Hospital, Chengdu, China, ⁴Health Inspection and Quarantine, Chengdu Medical College, Chengdu, China, ⁵Sichuan Provincial Key Laboratory for Disease Gene Study, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China

Ameliorating graft injury induced by ischemia and hypoxia, expanding the donor pool, and improving graft quality and recipient prognosis are still goals pursued by the transplant community. The preservation of organs during this process from donor to recipient is critical to the prognosis of both the graft and the recipient. At present, static cold storage, which is most widely used in clinical practice, not only reduces cell metabolism and oxygen demand through low temperature but also prevents cell edema and resists apoptosis through the application of traditional preservation solutions, but these do not improve hypoxia and increase oxygenation of the donor organ. In recent years, improving the ischemia and hypoxia of grafts during preservation and repairing the quality of marginal donor organs have been of great concern. Hemoglobin-based oxygen carriers (HBOCs) are “made of” natural hemoglobins that were originally developed as blood substitutes but have been extended to a variety of hypoxic clinical situations due to their ability to release oxygen. Compared with traditional preservation protocols, the addition of HBOCs to traditional preservation protocols provides more oxygen to organs to meet their energy metabolic needs, prolong preservation time, reduce ischemia–reperfusion injury to grafts, improve graft quality, and even increase the number of transplantable donors. The focus of the present study was to review the potential applications of HBOCs in solid organ preservation and provide new approaches to understanding the mechanism of the promising strategies for organ preservation.

Keywords: hemoglobin-based oxygen carriers, solid organ preservation, machine perfusion, organ oxygenation, ischemia–reperfusion injury

INTRODUCTION

Solid organ transplantation (SOT) is an optimal, lifesaving treatment choice for patients with end-stage organ failure. The number of transplants has increased dramatically in the last decade, but there remains a considerable imbalance between the demand and supply of donor organs worldwide (OPTN/SRTR 2019 Annual Data Report, 2021a, 2021b). According to the data from the OPTN/SRTR 2019 Annual Data Report about Deceased Organ Donation, donations after circulatory death (DCD) increased to 32,313 in 2019 from 29,675 in 2018 (Israni et al., 2021). Ischemia–reperfusion
injury (IRI) unavoidably occurs during organ resection and transplantation, may compromise the short-term and long-term after transplantation, and remains a critical organ transplantation challenge. With the increase in expanded criteria donor (ECD), the selection of better preservation methods to improve tissue oxygenation during isolated organ preservation to further reduce IRI of organs remains a pressing issue.

Ischemia and hypoxia are the leading causes of graft damage during the storage of isolated organs and may lead to a variety of destructive effects, such as ion imbalance, uncoupling of mitochondria, activation of endothelial cells, activation of various cell death programs, and proinflammatory immune responses (Kaliska et al., 2018; Lavallard et al., 2020). The current static cold storage (SCS) of grafts reduces enzyme activity and oxygen consumption, but the demand for energy metabolism and oxygen continues while cells maintain ion homeostasis and membrane potential (Kasai et al., 2019; Ali et al., 2020). Several methods for supplementing oxygen in organ preservation solutions have been reported. One method is the direct infusion of gaseous oxygen through mechanical perfusion platforms using various techniques, such as retrograde perfusion and supplemental oxygen under high pressure conditions (Higuchi et al., 2006; Minor et al., 2011; Tran et al., 2012). Supplemental oxygen during organ preservation promotes mitochondrial adenosine triphosphate (ATP) synthesis, prevents anaerobic metabolism, and reduces reperfusion injury (Minor et al., 2011). However, if the oxidative metabolism of the graft is severely impaired, direct oxygenation may exacerbate the oxidative stress damage to the organ. Another approach is to use oxygen carriers such as red blood cells (RBCs), humans, animals, recombinant sources, and perfluorochemicals (PFCs) (Tsujimura et al., 2002; Sakai et al., 2011; Teh et al., 2017; Liu et al., 2021). Perfusion of organs with blood as an oxygen carrier has been shown to reduce IRI to organs and improve grafts’ quality and short-term prognosis. However, blood has some potential disadvantages, including immune phenomena, blood infection, cross-matching and scarcity, and it can only be used for subnormothermic machine perfusion (SNMP) and normothermic machine perfusion (NMP) because RBCs can undergo hemolysis in a low-temperature environment (Cai et al., 2020; Lv et al., 2021). PFCs are hydrophobic, lipophilic, and difficult to disinfect, making it difficult to promote their use in clinical applications (Parlow et al., 2008). Therefore, researchers have been trying to find solutions that can provide oxygen close to physiological conditions during the preservation of isolated organs. Hemoglobin-based oxygen carriers (HBOCs) are a class of oxygen carriers that bind and release oxygen closer to physiological conditions than that of perfluorocarbons.

HBOCs are cell-free carriers obtained by processing free hemoglobin via chemical modification, genetic modification, or embedding (Standl et al., 2003). The oxygen affinity of some HBOCs is lower than that of human hemoglobin, thus facilitating oxygen release to tissues as the hemoglobin dissociation curve shifts to the right (Page et al., 1998). HBOCs were initially investigated as a blood substitute and have now been expanded for ischemic and hypoxic treatments. The application of HBOCs to the preservation of isolated organs may have several potential advantages: maintenance of cellular metabolic needs and mitigation of hypoxic damage; much lower diameter than that of RBCs for better oxygen delivery; no immune reactivity; the needs of the period of organ preservation; good stability for long storage time; wide range of temperature adaptation; and easy availability from a wide variety of sources. The effectiveness and safety of HBOCs in the preservation of grafts have been studied in numerous preclinical and clinical studies. This review summarizes the characteristics of HBOCs and presents recent advances in the preservation of solid organs in preclinical and clinical studies with the addition of HBOCs to the preservation solution.

**OVERVIEW OF HBOCS**

HBOCs are biological products obtained from purified hemoglobin (Hb) to have the ability to bind and release oxygen. Hb is a tetrameric protein molecule of ~64 kDa consisting of two noncovalently bound αβ dimers (Sahu et al., 2006). Free Hb released from aged or damaged RBCs dissociates in dimers that in plasma have a half-life only of a few hours (Bleeker et al., 1989). The released heme causes lipid peroxide- or H$_2$O$_2$-driven formation of ferryl myoglobin (Mb), which generates radicals and contributes to renal dysfunction (Moore et al., 1998; Alayash et al., 2007). Moreover, dimers are ultrafiltered in the kidneys, causing nephrototoxicity (Simoni et al., 1997). Hb cross-linking, polymerization, and conjugation to polymers prolong intravascular half-life, stability, and safety (Adachi et al., 1987; Boboñchak et al., 2003; Gordon et al., 2005). HBOCs were initially developed as blood substitutes. Numerous preclinical and clinical studies initially explored the safety and efficacy of HBOCs. HBOC-201 has been available in South Africa since 2001 and is approved for surgical patients with acute anemia (Mer et al., 2016). However, in 2008, Dr. Natanson and others included 13 randomized controlled trials in a meta-analysis of cell-free hemoglobin-based blood substitutes and concluded that the use of HBOCs was associated with a significantly increased risk of death and myocardial infarction (MI) based on an analysis of the available data (Natanson et al., 2008). Subsequently, the Food and Drug Administration (FDA) suspended all HBOC trials in the United States. The study of this meta-analysis generated widespread controversy. Related editorials suggested that if the imminent risk of death due to low Hb outweighed the risk of HBOCs, requiring a moratorium on all HBOC trials could be fatal for these patients (Levien et al., 2008; Sarani and Gracias, 2008; Sauaia et al., 2008). Since 2014, clinical trials for HBOCs are currently available only through expanded access (EA) to save patients’ lives when other interventions are not available (Mackenzie et al., 2010). HBOCs are presently approved for veterinary use in the United States, Russia, and the European Union (Jahr et al., 2008). Owing to the ability to bind oxygen and release oxygen, HBOCs have been extended for applications such as protection of isolated organs (van Leeuwen et al., 2019), initiation of
extracorporeal membrane oxygenation (ECMO) circuit as the pump-priming solution (York et al., 2002; Henderson et al., 2004), tumors (Belcher et al., 2020), and other ischemic and hypoxic diseases.

Based on the different sources of Hb, the main HBOCs applied for organ preservation are marine lugworm Arenicola marina (M101) (Arenicola marina), HBOC-201 (bovine), hemoglobin-vesicles (HbV) (human), polymerized human placenta hemoglobin (PolyPhb) (human), and hemoglobin glutamer (HbG) 200 (bovine). An overview of the different oxygen carriers used in solid organ preservation is provided to understand their properties better (Table 1). HBOCs of different origins have commonalities and dissimilarities. HBOCs have the advantages of no cell membrane, no blood type, no cross-matching requirements, no risk of viral infection, long-term storage, and timely availability, so they are excellent options for the preservation of isolated organs (Caswell et al., 2005). The molecular diameters of several HBOCs used for organ preservation (8–250 nm) are much smaller than those of RBCs (7,000 nm) and their viscosity is lower, thus making it easier for HBOCs not only to enter tissues through blood vessels and improve tissue oxygenation but also to promote oxygen diffusion in the microcirculation, resulting in a uniform distribution in the graft (Scatena and Giardina, 2001). Due to the different sources of Hb, different HBOCs also have their unique characteristics. M101 is a natural extracellular biopolymer Hb obtained from a marine invertebrate, Arenicola marina. M101 has a 3,600-kDa structure composed of 156 globins and 44 nonglobin linker chains that can carry up to 156 O₂ molecules when saturated (Toulmond et al., 1990; Zal et al., 1997; Rousselot et al., 2006). M101 possesses intrinsic Cu/Zn-superoxide dismutase antioxidant activity, protecting tissue from superoxide radicals to a certain extent (Rousselot et al., 2006). M101 is formulated as a good manufacturing practice (GMP)-compliant commercial class III medical device that is used as an additive to existing organ preservation solutions. HBOC-201 [hemoglobin glutamer-250 (bovine); Hemopure, HBO₂ Therapeutics LLC, Souderton, PA 18964, United States] is derived from bovine RBCs. Free Hb is then purified by chromatography and cross-linked with glutaraldehyde (GDA) to increase the stability and molecular size (Hughes et al., 1995; Callas et al., 1997). When fully saturated, HBOC-201 binds approximately 1.36 ml oxygen per gram of Hb. Since the Hb dissociation curve is shifted to the right, it releases oxygen more easily than human Hb (Callas et al., 1997; Dubé et al., 2008). PolyPhb is purified from fresh human placental blood, heat-treated to inactive it, and then intramolecularly and intermolecularly cross-linked with pyridoxal phosphate (PLP) and GDA. Then, ultrafiltration and molecular sieving chromatography are performed to obtain polyhemoglobin with a molecular weight of 64–600 kDa (Li et al., 2009). The HbV is a cellular-type HBOC involving polyethylene glycol (PEG), in which phospholipid vesicles encapsulating nearly 35–40 g/dl human Hb are embedded; the Hb concentration of the HbV suspension is 10 g/dl. One HbV particle (~250 nm diameter) contains approximately 30,000 Hb molecules (Sakai et al., 1996; Sakai et al., 2000; Sakai et al., 2001).

According to previous studies, direct infusion of HBOCs in the body can cause vasoconstriction, methemoglobin, and other side effects. The causes of vasoconstriction may include the following factors: scavenge nitric oxide (NO) (Standl, 2005), upregulated endothelin (ET) production (Taverne et al., 2017), the low viscosity and shear stress (Pearce and Gawryl, 2003), and vessel wall hyperoxegenation (Standl, 2005; Cabrales et al., 2009), of which the scavenging of NO is the leading cause of vasoconstriction. Hb in RBCs not only binds and transports oxygen in the circulation but also is an efficient scavenger of NO (Doyle and Hoekstra, 1981). However, the NO-scavenging rate of Hb in RBCs is reduced by a red cell–free zone along the endothelium in the blood, extracellular diffusion of NO to RBCs, and reduced NO diffusion over RBC membrane. All three of these mechanisms are eliminated by direct intravascular infusion of

### Table 1: Overview of different oxygen carriers in solid organ preservation.

| Product       | Current status | Company                                      | Source of Hb | Modification                        | Half-life | Size | Average particle diameter | P₅₀ | Shelf life |
|---------------|----------------|----------------------------------------------|--------------|-------------------------------------|-----------|------|--------------------------|-----|-----------|
| M101          | Clinical       | Hemaria, Morlaix, Brittany, France           | Marine       | Hexagonal bilayer-linked globin     | 2.5 days  | 3,600 kDa | 25 nm                    | 7 mmHg | N         |
| HBOC-201      | Clinical       | Acquired by Hemoglobin Oxygen Therapeutics in | Bovine       | Glutaraldehyde polymerization      | 19–24 h   | 250 kDa | 8 nm                     | 40 mmHg | 3 years   |
| HbV           | Preclinical    | Waseda Univ. & Keio Univ; Nara Medical University | Human       | Polyethylene glycol (PEG) chains   | 15–20     | N    | 250 nm                   | 9 mmHg | 2 years   |
| polyPhb       | Experimental   | Tianjin Union Stem Cell Genetic Engineering Ltd., Tianjin, China | Human       | Cross-linkage with glutaraldehyde | N         | 64–600 kDa | N                     | 5–9 mmHg | N         |
| HbG-200       | Preclinical    | Oxiglobin®, Biopure, Cambridge, MA          | Bovine       | Glutaraldehyde-polymerized         | 18–43 h   | 200 kDa | N                       | 34 mmHg | N         |
| Human red blood cells | Clinical   | N                                             | Human        | N                                   | 120 days  | 64 KDa | 7000 nm                  | 27 mmHg | 3 weeks   |

N, not reported; HbV, hemoglobin-vesicles; PolyPhb, polymerized human placenta hemoglobin; HbG, hemoglobin glutamer.
HBOCs, and the high affinity and low shear stress of HBOCs for NO also lead to a reduction in circulating NO (Jeffers et al., 2006). Thus, in the presence of free Hb, bioavailable NO is reduced and leads to vasoconstriction and hypertension, increased proinflammatory mediators and vasoconstrictive factors, and platelet inactivation (Loscalzo, 1997; Rother et al., 2005).

Although there are differences in these vascular parameters, there are few reports on vasoconstriction damage in the preservation of isolated organs. The following reasons may underlie the relative lack of reports: carbon monoxide (CO) production is increased during the degradation of heme (Alayash, 2017; Zhu et al., 2019); HBOCs provide a sufficient oxygen supply to cells, which may balance the effects of vascular parameters (Gould et al., 1998); the concentration of HBOCs during the preservation of isolated organs is much lower (de Vries et al., 2019); compared to protecting isolated organs from ischemia–reperfusion injury, the advantages of HBOCs outweigh the disadvantages (Topp et al., 2008); the lavage fluid neutralizes the HBOCs before they reach the recipient; and the concentration of HBOCs that eventually reaches the circulation is negligible (Mahboub et al., 2020). Unlike RBCs, HBOCs do not contain NADH-dependent methemoglobin reductase, which is responsible for converting methemoglobin back to Hb. The reversible oxygen binding of Hb to oxygen depends on the reduced state of iron atoms in the structure of Hb. However, one or more iron ions in methemoglobin are in the oxidized state and are unable to bind oxygen while increasing the affinity of Hb for oxygen and shifting the oxygen dissociation curve to the left, resulting in decreasing its ability to release and deliver oxygen (Dixit et al., 2021). However, elevated methemoglobin in the recipient has rarely been reported when HBOCs are applied to preserve grafts. This is possible because methemoglobin is washed out of the perfusion fluid before transplantation, making the amount of methemoglobin that eventually reaches the recipient’s circulation negligible.

Moreover, supplementation with additional HBOC-201, glutathione, vitamin C, and methylene blue also corrected or slowed the increased percentage of methemoglobin caused by HBOCs (de Vries et al., 2019; Mackenzie et al., 2010; Unnikrishnan et al., 2019). Therefore, applying conventional preservation solutions with added HBOCs to the preservation of isolated organs can adequately improve the oxygenation of tissues with fewer side effects. More importantly, more randomized clinical trials with large samples are needed to validate the safety and efficacy of HBOCs in SOT.

**HBOCs in Solid Organ Transplantation**

The preservation of isolated organs is necessary before transplantation into a recipient’s body. Thus, the choice of preservation solution is crucial for the protection of isolated organs. Countless traditional preservation solutions were developed with the increase in SOT in the 1970s, such as Euro-Collins (EC) (Ingemansson et al., 1995), Celsior, University of Wisconsin (UW), and histidine-tryptophan-ketoglutarate (HTK) solutions (Warnecke et al., 2002; Yoshida et al., 2002). The current mainstream organ preservation protocol is still to preserve organs in a standard conventional solution at 4°C. The purpose of preserving grafts in standard preservation solutions is to slow down the metabolic rate of tissue cells,
maintain the balance of substances inside and outside the cells, and reduce cell swelling (Gao et al., 2015; Tian et al., 2009). To further improve graft quality and recipient prognosis, several studies have reported the addition of sugars (Kobayashi et al., 1991), calcium ion antagonists (Ingemansson et al., 1996), potassium channel openers (Han et al., 2009), and platelet-activating factor antagonists (Kim et al., 2000) to the standard preservation solutions. However, the addition of these substances did not improve oxygenation of the tissues. The most fundamental cause of graft injury after removal from the donor is caused by ischemia and hypoxia. The conventional preservation solution with the addition of HBOCs is preoxygenated for a period of time, and the oxygenated solution will be used for static cold preservation and/or mechanical perfusion of the organ (Figure 1A). HBOCs exhibit good compatibility with traditional preservation solutions, and there is no need to modify the characteristics and protocols of organ preservation. Conventional preservation solution with HBOC added performs static cold preservation of the donor organ during the cold ischemic time (time from the perfusion of the organ with the solution to its removal from the cold storage for implantation) (Nakamura et al., 2020), a process that not only reduces cellular energy metabolism but also provides oxygen to meet organ oxygen demand (Figure 1B). The preservation solution containing HBOCs reduces ischemic and hypoxic damage to isolated organs, prolongs the preservation time of organs to meet long-distance transfer, and improves the utilization of organs to some extent. With the advancement of preservation technology and machines that simulate clinical reperfusion, isolated organs can be repaired and evaluated using the MP (machine perfusion) platform after long-distance cold preservation and transportation, which is especially beneficial for the use of marginal organs (Grundmann et al., 1977). Conventional preservation solutions with the addition of HBOCs are combined with different types of MP (hypothermic machine perfusion (HMP), SNMP, NMP, DHOPE [(dual) hypothermic oxygenated machine perfusion–controlled oxygenation rewarming (COR)-NMP]) for the repair and evaluation of marginal organs, which can improve the quality of marginal organs and patient prognosis, expanding to some extent the donor pool (Figure 1C). MP may be used as a platform for the dynamic circulation of isolated organs during preservation, and it induces a more even distribution of HBOCs in blood vessels, promotes the transport and diffusion of oxygen in the microcirculation, and improves the quality of the graft and the prognosis of the recipient (Fontes et al., 2015). Thus, the application of preservation solutions with HBOCs is similar to that of conventional preservation solutions and can be used directly for static cold preservation and mechanical perfusion of isolated organs without significant changes in protocol or equipment (Ali et al., 2020). HBOCs, as a class of oxygen carriers close to physiological conditions, can be used in various types of solid organs with multiple protocols for preservation. HBOCs are safe and feasible oxygen carriers that may be used for the preservation of organs in vitro (Figure 2). The application of HBOCs in different solid organs is discussed in detail below (Table 2).

**Heart**

Compared to other solid organs, the clinically isolated heart has a relatively short safe cold storage time (up to 4–6 h). The heart is an aerobic organ that relies on a continuous supply of oxygen to produce high-energy phosphate ATP for mechanical functions. The supply of oxygen via HBOCs supports the resynthesis of ATP.
### TABLE 2 | Studies evaluating the impact of HBOCs in solid organ transplantation.

| Author and year | Oxygen carrier | Evaluated solution | Concentration | Oxygenation | Experimental proposal | Species | Results | Author conclusion | Limitation/toxicity |
|-----------------|----------------|--------------------|---------------|-------------|------------------------|---------|---------|-----------------|-------------------|
| Heart Li et al. (2009) FREE RADICAL BIO MED 2009 | PolyPHb | STS | 5 g/L | Equilibrated with 96% O₂ and 5% CO₂ at 37°C for 30 min | Baseline (30 min; KHB); HS (8 h; 5 g Hb/dL PolyPHb + STS or blood or STS); 2 h KHB NMP | Sprague-Dawley rats | PolyPHb improved heart contraction, decreased infarction size and myocardial apoptosis, and maintained redox homeostasis | | N |
| Li et al. (2010) FREE RADICAL BIO MED 2010 | PolyPHb | STS | 0.1 g/dl | Equilibrated with 96% O₂ and 5% CO₂ at 37°C for 30 min | Sham (150 min perfusion; KHB) WI (30 min baseline KHB; 35 min STS WI; 2 h KHB NMP); WI + HBOC (30 min baseline KHB; 35 min STS + HBOC WI; 2 h KHB reperfusion); HS (30 min baseline KHB; 8 h STS; 2 h KHB NMP); HS + HBOC (30 min baseline KHB; 8 h STS + HBOC; 2 h KHB NMP) | Sprague-Dawley rats | PolyPHb improved cardiac function; decreased myocardial infarction, necrosis, and apoptosis; elevated mitochondrial function; and did not change the mitochondrial structure | Attenuated mitochondrial oxidative damage; preserved mitochondrial E₅₀ and SOD activity; preserved mitochondrial function; inhibited ROS burst; and depressed cytochrome c translocation | N |
| Wei et al. (2011) Cardiology 2011 | PolyPHb | HTKs | 0.3 g/dl | Equilibrated with 100% O₂ at 37°C for 5 min | Sham (150 min KHB perfusion) HTK9 (30 min baseline KHB; 9 h HTKs HS; 2 h KHB NMP); HBOC9 (30 min baseline KHB; 9 h HTKs + HBOC HS; 2 h KHB NMP); HTK14 (30 min baseline KHB; 14 h HTKs HS; 2 h KHB NMP); HBOC14 (30 min baseline KHB; 14 h HTKs + HBOC HS; 2 h KHB NMP) | Sprague-Dawley rats | HBOCs improved heart contraction and decreased infarct size, necrosis, and apoptosis; reduced expression of Toll-like receptor 2 (TLR 2), TLR 4, TNF-α, IL-1β, and nuclear factor-kB activation | Downregulated TLR 2 and TLR 4/NF-κB signaling pathway expression | Inhibitors of TLR 2 and TLR 4 were not used; did not research the relationship between different doses of PolyPHb and TLR 2 and TLR 4/NF-κB signaling pathway expression | (Continued on following page) |
### TABLE 2 | (Continued) Studies evaluating the impact of HBOCs in solid organ transplantation.

| Author and year | Oxygen carrier | Evaluated solution | Concentration | Oxygenation | Experimental proposal | Species | Results | Author conclusion | Limitation/toxicity |
|-----------------|----------------|--------------------|---------------|-------------|-----------------------|---------|---------|-------------------|---------------------|
| Teh et al. (2017) | M101 | Celsior | 1 g/L | Equilibrated with 95% O₂ and 5% CO₂ | 4–8°C cold storage 8 h (Celsior; Celsior + M101); KHB 60 min NMP | Wistar rats | Coronary flow was significantly higher in M101 group; improved postischemic recovery of heart function | Improved organ oxygenation | N |
| You et al. (2011) | PolyPHb | KHB | 0.1 g/dl | Equilibrated with 95% O₂ and 5% CO₂ for 10 min | Sham (perfused by KHB 2 h) Control (40 min baseline; 45 min WI; 2 h NMP) Ischemic preconditioning (10 min baseline; three 5-min ischemia and 5-min KHB perfusion; 45 min WI; 2 h NMP) deoxy-HBOCs (10 min baseline; three 5-min deoxygenated HBOC perfusion and 5-min KHB perfusion; 45 min W; 2 h NMP) | Sprague-Dawley rats | Decoxygenated HBOC pretreatment and ischemic preconditioning both equally improved the recovery of cardiac function and reduced the cardiac enzyme release and myocardial histopathology | Improved organ oxygenation | Ischemic preconditioning cannot block the aorta to induce cardiac ischemia; results cannot explain the cardioprotective mechanism |
| White et al. (2015) | HBOC-201 STEEN Solution | 40 g/L | N | RBC group (RBC + normal saline NMP 6 h); RBC + plasma group (whole blood NMP 6 h); HBOC group (HBOC-201 NMP 6 h); HBOC + plasma group (HBOC-201 + plasma NMP 6 h) | Domestic pigs | Whole blood–based perfusate minimized injury and provided superior preservation of myocardial function during NMP | HBOCs promoted spontaneous oxidation and ROS; HBOCs increased the proportion of methemoglobin and CVR; HBOCs increased troponin I levels and histologic myocardial injury scores | Did not directly quantify methemoglobin; did not directly test and confirm the efficacy of the filter in reducing circulating leukocytes. Methemoglobin mediated oxidative damage of endothelial cells |
| Lung Glorion et al. (2018) | M101 PerfadexV R (Xivivo, Sweden) | 2 g/L | N | Sham (similar to the recipient animals but without undergoing lung transplantation); Perfadex (4–6°C 24 h cold storage); M101 + Perfadex (4–6°C 24 h cold storage) | White pigs | M101 reduced graft vascular resistance and increased the graft oxygenation ratio | Improved organ oxygenation and decreased expression of HMGB1 | N |
| Ali et al. (2020) | M101 static cold storage (SCS) ex vivo | Low-potassium | 1 g/L | N | LPD (SCS 36 h + EVLP 12 h); M101 + LPD (SCS 36 h + EVLP 12 h); M101 + LPD (SCS 36 h + EVLP 12 h) | Yorkshire pigs | M101 provided better physiologic parameters and | Improved organ oxygenation; | Did not cause donor-related injuries before cold preservation; EVLP |

(Continued on following page)
| Author and year | Oxygen carrier | Evaluated solution | Concentration | Oxygenation | Experimental proposal | Species | Results | Author conclusion | Limitation/toxicity |
|----------------|----------------|-------------------|---------------|-------------|-----------------------|---------|---------|------------------|---------------------|
| **Liver**  
Topp et al. (2008) J SURG RES 2008 | HbG200 | KH-Sol | 3.3 g/dl | Equilibrated with 96% O₂ and 5% CO₂ | KH-Sol (EC cold storage 24 h; rat blood + KH-Sol IPRL 180 min); KH-Sol + HbG (EC cold storage 24 h; rat blood + KH-Sol + HbG IPRL 180 min); KH-Sol + 6% HES (EC cold storage 24 h; rat blood and + KH-Sol + 6% HES IPRL 180 min); KH-Sol + HbG + SnPP pretreated (EC cold storage 24 h; rat blood and + KH-Sol + HbG + SnPP IPRL 180 min) | Wistar rat | HBOCs increased HO-1 expression and activity during reperfusion, which could be abolished by tin protoporphyrin IX application | Improved organ oxygenation and induced HO-1; the antioxidant and anti-inflammatory properties of HO-1 | Endothelin-1–mediated vasoconstriction |
| **Fontes et al. (2015) AM J TRANSPLANT 2015** | HBOC-201 | UW | 3.5 g/dl | Oxygenated to \( \text{SaO}_2 > 95\% \) and \( \text{paO}_2 > 400 \text{ mmHg} \) | CSP (cold storage 9 h) MP (21°C, UW + HBOC 9 h) | Landrace pigs | MP/HBOC system had higher survival and superior graft function; oxygen delivered by the liver was 8 times that of oxygen intake; significantly improved liver preservation | Improved organ oxygenation | N |
| **Matton et al. (2018) LIVER TRANSPLANT 2018** | HBOC-201 | 20% Human albumin or 4% gelofusine | 18.3 g/L | Equilibrated with 96% O₂ and 5% CO₂ | RBC + FFP (6 h NMP); HBOC-201 + FFP (6 h NMP); HBOC-201 + gelofusine (6 h NMP) | Human | HBOC-201 had significantly higher hepatic adenosine triphosphate content, cumulative bile production, and portal and arterial flows | Improved organ oxygenation | Relatively small sample sizes; lack of transplant validation; study grouping was performed consecutively rather than after randomization |

(Continued on following page)
| Author and year | Oxygen carrier | Evaluated solution | Concentration | Oxygenation | Experimental proposal | Species | Results | Author conclusion | Limitation/toxicity |
|----------------|----------------|-------------------|--------------|-------------|-----------------------|---------|---------|-------------------|-------------------|
| Laing et al. (2017) Transplantation 2017 | HBOC-201 | Modified Ringer’s lactate solution | 63.7 g/L | Oxygenated to arterial $\text{PO}_2 = 20$ kPa | HBOCs (Hemopure-based perfusion fluid 6 h NMP); RBCs (packed red blood cell-based fluid 6 h NMP) | Human | HBOC-perfused livers extracted more oxygen than those perfused with RBCs | Improved organ oxygenation; exhibited antioxidant activity | Livers were not transplanted. Did not simulate the reperfusion with whole blood containing immune cell populations |
| van Leeuwen et al. (2019). Ann Surg 2019 | HBOC-201 | UW N | | DHOPE; oxygenated to $\text{PaO}_2 > 80$ kPa | 1 h DHOPE; 1 h COR; 150 min NMP | Human | 69% of livers that met all viability criteria were successfully transplanted; 100% graft survival at 3 and 6 months; DHOPE-COR-NMP increased the number of deceased donor liver transplants by 20% | Improved organ oxygenation | Lack of randomization; livers were not transplanted based on a low bile pH during NMP, and therefore have no follow-up |
| Shonaka et al. (2019) PLoS One 2019 | HbV | UW N | N | CS (WIT 1 h, CS 4 h); HMP (WIT 1 h, HMP 4 h); SNMP (WIT 1 h, SNMP 4 h); SNMP + HbV (WIT 1 h, SNMP + HbV 4 h) | Female cross-bred Large-Yorkshire, Landrace, and Duroc pigs | Increasing oxygenation and oxygen consumption, maintained mitochondrial structure and function, and had a protective effect on metabolic acidosis | Transplantation was not performed, and these results are not sufficient for predicting the effects of SNMP/HbV in a living body |
| Alix et al. (2020) JHEP Rep 2020 | M101 | UW | 1 g/L N | SCS (cold storage, UW 6 h); SCS + M101 (cold storage, UW+1 g/L M101 6 h); HOPE (HOPE, UW+1 g/L M101) | White/Landrace x Pietrain pigs | M101 effectively oxygenated liver grafts during preservation; prevented posttransplant injury without reaching the level of HOPE | Improved organ oxygenation and preserved ATP synthase activity | Two different solutions were used in the SCS and HOPE groups; no medicoeconomic data available regarding the potential benefit of M101 in liver transplantation |
| Boteon et al. (2019) PLoS One 2019 | HBOC-201 | UW N | Equilibrated with 30% $\text{O}_2$ 1-2 L/min | HOPE + NMP (UW + HOPE 2 h; UW + HBOC-201 + NMP 4 h); cold-to-warm group (UW + HBOC-201 + HOPE, gradually warmed, | Human | Both HMP + NMP and cold-to-warm mitigated the oxidative-mediated tissue injury and enhanced hepatic energy stores; HMP + NMP simplified | Improved organ oxygenation and enhanced ATP synthesis | Relatively small sample sizes; organs were not transplanted; replacement of the perfusate may reduce toxic metabolites; unable to evaluate transaminases or other markers of oxidative stress in the perfusate; (Continued on following page) |
| Author and year | Oxygen carrier | Evaluated solution | Concentration | Oxygenation | Experimental proposal | Species | Results | Author conclusion | Limitation/toxicity |
|----------------|----------------|--------------------|--------------|-------------|-----------------------|---------|---------|------------------|------------------|
| de Vries et al. (2019) | HBOC-201 | UW | N | 3-Month graft survival was 100% | DHOPE, 10°C 1 h; COR, the temperature was gradually increased approximately 1°C per 2 min to 37°C; NMP, 37°C 1 h | Human | The 3-month graft survival rate was 100% | Improved organ oxygenation | Absolute values and proportional ATP increase were lower than those in other studies performing HOPE; lack of further data on the histology of the bile duct. Relatively small sample sizes and lack of a control group; did not draw conclusions on the value of the COR phase; did not discriminate between the beneficial effects of DHOPE, COR, and NMP separately; HBOCs were converted to methemoglobin, especially in the venous phase. |
| Shonaka et al. (2018) | HbV | UW | 0.6-0.7 mg/dl | N | Group 1 (cold storage UW 240 min, reperfusion with autologous diluted blood 120 min); Group 2 (SNMP (20-22°C) UW 240 min, reperfusion with autologous diluted blood 120 min); Group 3 (SNMP HbV and UW 240 min, reperfusion with autologous diluted blood 120 min) | Female cross-bred Large-Yorkshire, Landrace, and Duroc pigs | HbV increased the oxygen consumption of the donor liver during SNMP | Improved organ oxygenation | Animal model; experiment on the transplant model, and therefore, the result of the actual transplant is unknown. |
| Kidney Thuillier et al. (2011), AM J TRANSPLANT 2011 | M101 | UW or HTK | 1 g/L | N | Controls (sham-operated); UW (CS 24 h); UW + 5 g/L LM101 (CS 24 h); HTK (CS 24 h); HTK + 5 g/L M101 (CS 24 h) | Large white male pig | HBOCs lowered the peak of serum creatinine, reduced kidney inflammation levels, and maintained structural integrity; improved survival and function; and slowed the advance of interstitial fibrosis | Improved organ oxygenation and provided SOD activity | N |
| Mallet et al. (2014) | M101 | UW | 1 g/L; 2 g/L; 5 g/L | N | UW solution (CS 24 h); UW+ 1 g/L M101 (CS 24 h); | Large white male pigs | Cells preserved better with HEMO2Life in a | Improved organ oxygenation | N |

(Continued on following page)
| Author and year       | Oxygen carrier | Evaluated solution | Concentration | Oxygenation | Experimental proposal                                                                 | Species            | Results                                                                                                                                   | Author conclusion                                                                                       | Limitation/toxicity                                                                                     |
|----------------------|----------------|--------------------|---------------|-------------|----------------------------------------------------------------------------------------|--------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Mahboub et al. (2020) | HBOC-201       | UW 25%             | Equilibrated with 95% O₂ and 5% CO₂, SaO₂ > 97% |                            | UW (37°C 30 min, CS 4°C 120 min, rewarming 90 min 10–37°C, anastomosis 30 min 21°C, reperfusion 37°C 120 min with HBOCs + UW); HBOCs (37°C 30 min, CS 4°C 120 min, rewarming 90 min 10–37°C with HBOCs, anastomosis 30 min 21°C, reperfusion 37°C 120 min with HBOCs) | Lewis rats         | HBOCs improved kidney function and ultrafiltrate production, and improved glomerular filtration rate and sodium reabsorption         | Improved organ oxygenation                                                                             | Lack of transplantation validation; did not specifically study the O₂ carrying capacity; Methemoglobin increased slightly and more during reperfusion |
| Aburawi et al. (2019) | HBOC-201       | Williams E Media 3.5 g/dl | Equilibrated with 95% O₂ and 5% CO₂ | HBOCs (6 h NMP); PRBCs (6 h NMP) |                                                            | Human              | HBOC/NMP system was feasible and did not result in inferior outcomes compared to PRBCs                                            | Improved organ oxygenation                                                                             | Relatively small sample sizes; lack of transplantation or a simulated reperfusion component            |
| Kasil et al. (2019)  | M101 Perf-GEN preservation solution | 2 g/L N            | Group W (1 h WI, 23 h HMP); Group W-O₂ (1 h WI, 23 h HMP oxygenated with 100% O₂ at 1 L/ min); Group W-M101 (1 h WI, 23 h HMP+2 g/L M101); Group W-O₂ + M101 (1 h WI, 23 h HMP oxygenated with 100% O₂ at 1 L/ min+2 g/L M101) | White pigs        | M101 associated with or without 100% O₂ improved kidney recovery and late graft outcome | Provided intrinsic SOD activity and regulated pH; maintained ROS/anti-ROS balance |                                                                                                      | N                                                                                                       |
| Bhattcharjee et al. (2020) | HBOC-201      | HTK HBOC-201        | Oxygenated to 40% | SCS (30 min WI, CS HNK 8 h) 22°C blood | Landrace pigs had similar renal blood                                                                 | HBOC-201          | Improved organ oxygenation;                                                                                                           |                                                                                                          | N                                                                                                     |
| Author and year | Oxygen carrier | Evaluated solution | Concentration | Oxygenation | Experimental proposal | Species | Results | Author conclusion | Limitation/toxicity |
|----------------|----------------|--------------------|---------------|-------------|------------------------|---------|---------|-----------------|--------------------|
| Kaminski et al. (2019) | M101 | UW (CS) | 1 g/L or N | CS-0 (60 min WI, CS UW 23 h ± 30 min); CS-1 (60 min WI, CS UW 1 h, M101 23 h ± 30 min); MP-0 (60 min WI, HMP KPS 23 h ± 30 min); MP-1 (60 min WI, HMP KPS+1 g/L 23 h ± 30 min); MP-2 (60 min WI, HMP KPS+2 g/L 23 h ± 30 min); SHAM (sham-operated); NEP (nephrectomized) | Large white male pigs | Cs arm: M101 dose-dependently improved long-term function MP arm: M101 improved short and long-term functional outcomes as well as tissue integrity | Improved organ oxygenation and increased ATP resynthesis and VEGF expression |
| Le Meur et al. (2020) | M101 | UW | 1 g/L | N | M101 (CS or MP); UW (CS or MP); M101 added to the preservation solution of one of two kidneys from the same donor | Human | M101 significantly reduced DGF and improved renal function | Improved organ oxygenation |
| Avila et al. (2006) Am J Transplant 2006 | Polymerized human hemoglobin | Poly SFH-P 10 g/dl | Equilibrated with 100% O₂ for 15 min | Poly SFH-P (30 min WI; 37°C 18 min perfusion); Control (30 min WI; 37°C 18 min perfusion) | Lewis rats | Poly SFH-P improved islet isolation; oxygenation and preserved mitochondrial integrity | Improved organ oxygenation; improved islet viability; and improved integrity of both beta and non-beta cells |
| Espes et al. (2015) Transplantation 2015 | PolyHb | Phosphate buffer (PB) | 106.79 mg/ml | N | PolyHb (0.03 mg/gl); PolyHb (0.1 mg/gl); PolyHb (0.3 mg/gl); Male C57BL6 | Male C57BL6/6 nu/nu mice | PolyHb effectively bridged the critical hypoxic phase immediately after transplantation, | Improved organ oxygenation | Macrophages were attracted by the presence of the hemoglobin–haptoglobin complex in the high-dose treatment (Continued on following page) |

TABLE 2 (Continued) Studies evaluating the impact of HBOCs in solid organ transplantation.
### TABLE 2 (Continued) Studies evaluating the impact of HBOCs in solid organ transplantation.

| Author and year | Oxygen carrier | Evaluated solution | Concentration | Oxygenation | Experimental proposal | Species | Results | Author conclusion | Limitation/toxicity |
|-----------------|----------------|--------------------|---------------|-------------|------------------------|---------|---------|------------------|----------------------|
| Lemaire et al. (2019) | M101 | 2 g/L | Hanks’ Balanced Salt Solution (HBSS) | N | Cold storage (HBSS + M101 0, 2, 4, 6, 8, 12, and 18 h); Perfusion: 4°C 6 h with M101 or without M101 | Wistar rat | Improved islet graft function, and reduced the number of islets needed for successful intramuscular transplantation | M101 decreased oxidative stress (ROS) and necrosis (HMGB1); cellular stress pathway (p38 MAPK) activity was observed; improved post-isolation islet quality | Maintained oxidative phosphorylation; improved organ oxygenation; intrinsic SOD-like activity |
| Lemaire et al. (2019) | M101 | 2 g/L | UW | N | Cold storage (SCS 6 h + M101 3 h) | Human | M101 increased complex 1 mitochondrial activity and activated AKT activity; upregulated insulin secretion | Maintained oxidative phosphorylation; improved organ oxygenation; intrinsic SOD-like activity | N |
| Huang et al. (2014) | pPolyHb | UW | 10.5 ± 0.5 g/dl | Equilibrated with 95% O₂ and 5% CO₂ for 30 min | Group 1: UW solution (SCS 12, 24, and 36 h); Group 2: HCA solution with 2 g/dl pPolyHb (SCS 12, 24, and 36 h); Group 3: HCA solution with 4 g/dl pPolyHb (SCS 12, 24, and 36 h); Group 4: HCA solution (SCS 12, 24, and 36 h) | Sprague-Dawley rats | Long-term (36 h) morphological integrity of the intestinal mucosa was better preserved in the pPolyHb; maintained tissue aerobic respiration and inhibited tissue anaerobic metabolism | Improved organ oxygenation | N |

STS, St. Thomas’ solution; HS, hypothermic storage; CS, cold storage; NMP, normothermic machine perfusion; NO, nitric oxide; KHB, Krebs-Henseleit buffer; WI, warm ischemia; SOD, superoxide dismutase; HTK, histidine-tryptophan-ketoglutarate; KH-Sol, Krebs-Henseleit solution; ROS, reactive oxygen species; TLR, toll-like receptor; RBBC, red blood cell; PRBC, packed red blood cells; CVR, cerebrovascular resistance; LPD, low-potassium dextran solution; EVLP, ex vivo lung perfusion; SnPP, Sn-protoporphyrin; HD-1, herne oxygenase-1; IPRL, isolated perfused rat liver; UW, University of Wisconsin; MP, machine perfusion; FFP, fresh frozen plasma; DHOPE, hypothermic oxygenated machine perfusion; COR, controlled oxygenated rewarming; SCS, static cold storage; ATP, adenosine triphosphate; SNMP, subnormothermic machine perfusion; HVMP, hypothermic mechanical perfusion; KPS, kidney preservation solution; SFH-P, stroma-free hemoglobin pyridoxalated; HBSS, Hanks’ Balanced Salt Solution; HMGB1, high mobility group box; AKT, serine threonine kinase; HCA, hypertonic citrate adenine.
in mitochondria of isolated heart tissue, which delays the damage of ischemia and hypoxia and extends the cold storage time (Teh et al., 2017). Li et al. were the first to find that PolyPHb protected isolated hearts from cold IRI by attenuating the expression of toll-like receptor 2 (TLR2) and toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-kB) signaling pathways (Wei et al., 2011). The addition of M101 to Celsior preservation solution significantly improved cardiac function recovery after ischemia, and the coronary blood flow and left ventricular development pressure (LVDP) recovered significantly after 60 min of reperfusion (Teh et al., 2017).

The studies mentioned above confirmed that HBOCs reduced the IRI of the isolated heart and improved aerobic metabolism and myocardial function. However, an HBOC-201–based perfusate restored myocardial energy storage and extracted oxygen faster than blood-based perfusion during ex vivo heart perfusion (EVHP) to meet the needs of myocardial metabolism, but it did not minimize myocardial injury or provide superior preservation of myocardial function (White et al., 2015). These effects may be due to HBOC-201–mediated reactive oxygen species (ROS) generation and the increase in methemoglobin (White et al., 2015), which caused cardiac endothelial cell injury and increased microvascular permeability and coronary vascular resistance (CVR) and ultimately led to myocardial edema and cardiac diastolic dysfunction. HBOC-201 may also have a unique mechanism of myocardial injury that leads to increased levels of troponin I and histological myocardial injury scores (White et al., 2015). Whether reducing the dose of HBOC-201 and incorporating additional antioxidants will optimize the preservation of the donor’s heart during EVHP is unclear and needs further verification in larger studies.

**Liver**

Liver graft quality depends on the donation status of the donor and the preservation effect during transportation from the donor to the recipient. During the preservation of the isolated liver, insufficient oxygen supply followed by reperfusion leads to an inflammatory network, and oxidative stress in the tissue leads to IRI. HBOCs induce the production of heme oxygenase 1 (HO-1) (Damle et al., 2009). Topp and Donner et al. confirmed that the positive effect of reducing isolated liver IRI depended on the induction of HO-1, which may be inhibited by tin protoporphyrin IX dichloride (SnPP) (Donner et al., 2013; Topp et al., 2008). By inducing HO-1, HbG200 largely restored multidrug resistance–associated protein 2 (Mrp2) and bile salt export pump (Bsep) in pericentral hepatocytes and improved bile flow and biliary taurocholate excretion, which are related to diminished hepatocellular c-Jun N-terminal kinase (JNK) and Fyn signaling. Biliverdin/bilirubin and CO, which are the breakdown products of HO-1, also regulate JNK activity. Compared to traditional static cold preservation, both hypothermic oxygenated machine perfusion (HOPE) and SCS + M101 effectively oxygenated and increased ATP synthesis during the preservation of the isolated liver and prevented injury after liver transplantation (Ali et al., 2020). This study showed that HOPE had better results than M101 supplements, which may be related to the constant supply of oxygen and continuous capillary...
network flushing during liver perfusion. Nevertheless, SCS + M101 preservation for non-high-risk donor livers will be more convenient and easier to implement due to the high cost, manpower support, and risks of vascular injury associated with the use of HOPE. Compared to the current standard-of-care (CSP) system, the SNMP/HBOC system also significantly improved preservation of the isolated liver and provided superior graft function and 100% survival after transplantation, which may be further extended to the recovery and improvement of grafts obtained by ECDs (Fontes et al., 2015). In a pig model of DCD, HbV significantly increased the oxygen consumption of the donor’s liver during SNMP, but it did not prevent liver injury because the amount of HbV (0.6–0.7 g/dl) was insufficient (Shonaka et al., 2018). However, another study showed that SNMP + HbV solution reduced reperfusion injury in DCD donor livers (Shonaka et al., 2019).

Mitochondria, pH, and lactate levels of the SNMP + HbV group were well maintained compared to the cold storage (CS), HMP, and SNMP groups. NMP is generally performed using perfusion solutions based on RBCs to maintain physiological osmolarity, oncotic pressure, and adequate metabolic support. Laing et al. presented the first experience using an HBOC-based perfusion fluid to perfuse five discarded high-risk human livers in a human model of NMP (Laing et al., 2017). Livers perfused using the NMP/HBOC system had similar vascular flow parameters and perfused lactate clearance as the RBC-based perfusate but extracted more oxygen, which may be more beneficial in logistics, rheology, and immunology (Laing et al., 2017). Therefore, HBOC-201 may be used as an alternative oxygen carrier for RBCs in NMP. Matton et al. also reported that HBOC-201–based perfusate could be effective for NMP by using HBOC-201 + gelofusine perfusate instead of RBCs + FFP perfusate, while the results of some biomarkers of liver function and injury were even better without the use of human blood products (Matton et al., 2018). COR mitigates reperfusion injury and improves graft function posttransplantation (Hoyer et al., 2016). Boteon et al. reported that after perfusion of human high-risk donor livers using a combined cold-to-warm uninterrupted combined protocol (a single HBOC-based perfusate) and the HOPE + NMP interrupted combined protocol, both protocols reduced oxidation-mediated tissue injury and enhanced hepatic energy stores (Boteon et al., 2019). It showed that the combined protocol of COR and HBOC is beneficial for repairing high-risk donor livers while also eliminating the additional ischemic time required for perfusate exchange and simplifying the logistics of this combination, which may benefit its clinical application. de Vries et al. first reported that after serial DHOPE-COR-NMP using HBOC-201-based perfusate in seven high-risk donor livers, five of them were transplanted into recipients after evaluation that met all of the following transplantation criteria: within 150 min of NMP perfusate lactate <1.7 mmol/L, pH 7.35–7.45, bile production >10 ml, and bile pH > 7.45 (de Vries et al., 2019). Similarly, in a prospective clinical trial by van et al., after perfusion of 16 high-risk donor livers with HBOC-201-based perfusion solution combined with DHOPE-COR-NMP, 11 of these donor’s livers were transplanted into recipients after repair and evaluation of the liver and the survival of patients and grafts was 100% at 6 months (van Leeuwen et al., 2019). The study ultimately showed that the introduction of HBOCs in combination with DHOPE-COR-NMP could increase the number of high-risk donor liver transplants by 20% at the center. HBOC in combination with MP has been applied to the preservation of high-risk donor livers in clinical settings and has achieved a relatively favorable prognosis. However, randomized clinical trials with larger samples should be implemented to verify the benefits and prospects they offer, and the longer-term prognosis of the recipients should continue to be closely observed.

Kidney

Kidney transplantation is the therapy of choice for end-stage renal diseases. IRI is a complex process that involves oxidative stress, mitochondrial uncoupling, and the coagulation cascade, which affect early graft function after organ transplantation and have an adverse effect on the long-term survival of grafts (Favreau et al., 2010). Thuillier et al. found that supplementation of M101 in UW or HTK solution reduced apoptosis and maintained mitochondria in a time- and dose-dependent manner during cold preservation in a pig kidney auto-transplantation model, with significant benefits in both early functional recovery and prognosis after transplantation, and reduced the occurrence of IRI and interstitial fibrosis and tubular atrophy (IFTA) (Thuillier et al., 2011). Similarly, Mallet et al. also presented a dose-dependent reduction in the extent of IRI and improved prognosis of grafts after cold preservation of porcine kidneys with UW solution supplemented with M101, and benefits were also obtained with lower doses of M101 (1 g/L) (Mallet et al., 2014). As high-risk donor kidneys are more prone to severe ischemia–reperfusion injury, there is an increased probability of delayed injury and dysfunction in the recipient and the graft (Oberbauer, 2016). As the demand for organ transplantation increases, repairing and assessing the quality of high-risk donor organs and improving the utilization of high-risk organs are among current solutions to expand the number of transplantable organs. Preservation of high-risk donor livers using SCS + M101 also showed dose-dependent improvement in long-term graft function; similarly, combining M101 with HMP had an improved effect on both short- and long-term graft function after transplantation (Kaminski et al., 2019). The combination of MP with HBOC allows for a uniform distribution of the HBOC in the vascular lumen and a more efficient delivery of oxygen to the tissues, further reducing ischemic and hypoxic injury and repairing the graft mass. HBOCs improve tissue oxygenation and repair kidney quality by releasing oxygen. However, if pure oxygen is added to the preservation solution for organ preservation, will the expected benefits be consistent? Kasil et al. evaluated the effect of supplemental oxygen [(100% O2) ± M101 (respectively or combined)] with HMP on the perfusion of isolated kidneys in a pig kidney auto-transplantation model (Kasil et al., 2019). The results showed that using 100% O2 in HMP without supplementation with M101 was harmful to the kidneys, which manifested as delayed vimentin expression and did not limit renal fibrosis. In
addition, the combination of M101 and 100% O2 reduced the level of neutrophil gelatinase-associated lipocalin (NGAL) and maintained a high level of kidney injury molecule-1 (KIM-1) in the circulation. The study showed that supplementation with M101 with or without 100% O2 improves the HMP effect on kidney recovery and late graft results.

Gradual rewarming is a new perfusion modality in which HBOC maintains the preservation of perfusion of organs from hypothermia to normothermia. A transient increase in vascular resistance and methemoglobin was observed after preservation of the kidney using a preservation solution supplemented with HBOC-201 in a model of gradual rewarming but improved ultrafiltrate production, glomerular filtration rate, and sodium reabsorption during the reperfusion phase (Mahboub et al., 2019). In the context of combination with MP, the risk of HBOC-201 causing a transient increase in vascular resistance and methemoglobin transfer to the organ recipient is negligible because HBOC and methemoglobin will be washed out before transplantation. Perfusion preservation of organs using blood cannot be performed at low temperatures because it can lead to hemolysis and impair the quality of the grafts. Bhattacharjee et al. perfused porcine DCD kidneys with HBOC-201 or blood in combination with SNP and found that tissue oxygen saturation, renal blood flow, and function were similar in both groups (Bhattacharjee et al., 2020). Thus, this demonstrated that HBOC-201 is a suitable oxygen carrier capable of replacing blood. NMP is capable of perfusing and repairing organs in combination with oxygen carriers and assessing the quality of the grafts. Mohamed et al. used HBOCs or packed red blood cells (PRBC) combined with NMP for perfusion and evaluation of human high-risk donor kidneys and found that the function and histological characteristics of the kidney were similar (Aburawi et al., 2019). This study confirmed that the HBOC solution could provide a logistically convenient alternative to PRBC in the NMP of human kidneys. Meur et al. demonstrated for the first time the safety and performance of the addition of M101 to the preservation solution of one of the two human kidneys from the same donor in a multicenter open-label study (Le Meur et al., 2020). This study showed that kidneys preserved with the addition of M101 showed no alterations in thrombosis or microcirculation on biopsy before implantation and 3 months after transplantation and had significantly less DGF and better kidney function after transplantation. The use of M101 for kidney preservation has been applied clinically and has confirmed the safety and promising efficacy data of M101 (Le Meur et al., 2020).

**Pancreas and Small Bowel**

Pancreas or islet transplantation is a treatment for type 1 diabetes and pancreatitis (Barrou et al., 1994). During the preservation and isolation of islets, maintenance of proper oxygen levels is of great importance to prevent ischemia and reperfusion injury (Carlsson and Palm, 2002). Avila et al. showed that intratubular perfusion of HBOCs in the pancreas of rats undergoing 30 min of warm ischemia improved islet isolation and transplantation outcomes via maintaining mitochondrial integrity and did not lead to increased oxidative stress (Avila et al., 2006). M101 was added to the preservation solution during cold preservation of rat and human pancreas, and hypoxia and the oxidative stress of SOD were reduced, which alleviated tissue inflammation and necrosis (Lemaire et al., 2019). Overall, these results suggested that M101 had a positive effect on preserving the pancreas in rats and humans.

Muscle is a promising alternative site for islet transplantation, facilitating the rapid restoration of islet vasculature; however, it is susceptible to hypoxic limitation in the early posttransplant period. By co-transplanting islets with an oxygen carrier-PolyHb in mice, Daniel et al. found a dose-dependent reduction in β-cell hypoxia (Espes et al., 2015). Yet, the morphology of islets was significantly disrupted by the higher concentration of a bovine polyhemoglobin (PolyHb) inducing the aggregation of a large number of macrophages, and the reduction in β-cell apoptosis occurred only in the low-dose group (0.03 mg/g body weight). Lower doses of PolyHb co-transplanted with islets effectively bridged the critical hypoxic phase after transplantation, improved islet graft function, and reduced the number of islets required for successful intramuscular transplantation. In contrast, the inflammatory effect of higher concentrations of PolyHb may be due to the attraction of macrophages to the Hb–haptoglobin complex. HBOCs have also been used in rat small bowel preservation (Huang et al., 2014). This study suggested that hypertonic adenine citrate solution (HCA) combined with pPolyHb maintained tissue aerobic respiration and inhibited anaerobic metabolism with a preservation effect comparable to that of UW solution.

**OVERALL CONCLUSION AND FUTURE PERSPECTIVES**

Due to the global shortage of organ resources, the imbalance of donor–recipient needs, and the increasing number of high-risk donors, these issues have led to considering what should be done to preserve grafts better. Although standard preservation solutions are currently used for static cold preservation, the repair and evaluation of marginal organs may rely on multiple combinations of MP, oxygenation strategies, and temperature regulation. Many efforts have been made by clinical practitioners and researchers to explore ways to mitigate graft ischemia–reperfusion injury, improve graft quality, and increase recipient and graft survival rates. Originally developed and utilized as a blood substitute, HBOCs are an ideal class of oxygen carriers with the ability to bind oxygen and release oxygen. HBOCs have now been extended to apply to tissues or organs in hypoxic conditions, where they act as an oxygen bridge to improve tissue oxygenation. The addition of HBOC to the preservation solution to improve the quality of the graft is a new promising strategy because they offer several advantages compared with traditional preservation solutions. First, HBOCs improve the oxygenation of isolated organs during SCS and enhance the quality of grafts. Second, the combination of HBOCs and MP provides a more targeted method, which can replace RBC perfusion to improve and evaluate the quality of high-risk grafts. In addition, preservation solutions containing HBOCs may be easily used in all solid organ transplants without...
further improving the existing preservation solution or perfusion platform protocols. Recent clinical trials have demonstrated the safety and efficacy of HBOCs in combination with mechanical perfusion platforms for liver and kidney preservation and improved prognosis for recipients and grafts.

Future prospects address the need for translational medicine research to determine the exact therapeutic dose and organ preservation time for human solid organs. Coordinated multicenter clinical trials are also needed in the subsequent clinical studies to accumulate larger, homogeneous cohorts. Additionally, some clinical trials with a randomized controlled design would be performed. This review summarizes the latest and most important research on HBOCs in solid organ preservation. Therefore, based on scientific evidence, HBOCs, one of the oxygen carriers for organ preservation, are ideal candidates for organ preservation additives. The mechanism of organ preservation by HBOCs has not been fully understood; the relevant mechanism would be investigated in depth in future studies to determine a more optimal preservation method. In addition, the vascular resistance, methemoglobin content, and oxidative damage index of grafts and recipients would also be closely monitored when using HBOCs. The future development of HBOCs may give a fascinating insight into the understanding of the safety and effectiveness of new strategies for solid organ preservation.

AUTHOR CONTRIBUTIONS

MC, GW, and HH were responsible for the organization and preliminary analysis of the literature; RY, YZ, LP, WH, YG, TY, and LM were involved in the data collection and collation; MC, DZ, and XH were responsible for the conceptualization and writing of the original draft; DZ and XH contributed to the final edits and general revisions. All authors have read and approved the final version of the manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (81470667), Department of Science and Technology of Sichuan Province (20YJ0435), and Science & Technology Bureau of Chengdu (YF06-00070-SN and YF05-00198-SN).

REFERENCES

Aburawi, M. M., Fontan, F. M., Karimian, N., Eymard, C., Cronin, S., Pendexter, C., et al. (2019). Synthetic Hemoglobin-Based Oxygen Carriers Are an Acceptable Alternative for Packed Red Blood Cells in Normothermic Kidney Perfusion. *Am. J. Transpl.* 19, 2814–2824. doi:10.1111/ajt.15375

Adachi, K., Kim, J., Travitz, R., Harano, T., and Asakura, T. (1987). Effect of Amino Acid at the Beta 6 Position on Surface Hydrophobicity, Stability, Solubility, and the Kinetics of Polymerization of Hemoglobin. Comparisons Among Hb A (Glu Beta 6), Hb C (Lys Beta 6), Hb Machida (Gln Beta 6), and Hb S (Val Beta 6). *J. Biol. Chem.* 262, 12920–12925. doi:10.1016/0021-9228(87)91454-9

Alayash, A. I., D’Agnillo, F., and Buchler, P. W. (2007). First-generation Blood Substitutes: what Have We Learned? Biochemical and Physiological Perspectives. *Expert Opin. Biol. Ther.* 7, 665–675. doi:10.1517/14712598.7.5.665

Alayash, A. I. (2017). Hemoglobin-Based Blood Substitutes and the Treatment of Sickle Cell Disease: More Harm Than Help. *Biomolecules* 7, 2. doi:10.3390/biom7010002

Ali, A., Watanabe, Y., Galasso, M., Watanabe, T., Chen, M., Fan, E., et al. (2020). An Extracellular Oxygen Carrier during Prolonged Pulmonary Preservation Improves post-transplant Lung Function. *J. Heart Lung Transpl.* 39, 595–603. doi:10.1016/j.healun.2020.03.027

Alix, P., Val-Laillet, D., Turlin, B., Ben Mosbah, I., Burel, A., Bobillier, E., et al. (2020). Adding the Oxygen Carrier M101 to a Cold-Storage Solution Could Be an Alternative to HOPE for Liver Graft Preservation. *JHEP Rep.* 2, 100119. doi:10.1016/j.jhep.2020.100119

Avila, J. G., Wang, Y., Barbaro, B., Gangemi, A., Qi, M., Kuechle, J., et al. (2006). Improved Outcomes in Islet Isolation and Transplantation by the Use of a Novel Hemoglobin-Based O2 Carrier. *Am. J. Transpl.* 6, 2861–2870. doi:10.1111/j.1600-6143.2006.01511.x

Barrou, Z.,Seaquist, E. R., and Robertson, R. P. (1994). Pancreas Transplantation in Diabetic Humans Normalizes Hepatic Glucose Production during Hypoglycemia. *Diabetes* 43, 661–666. doi:10.2337/diab.43.5.661

Belcher, D. A., Lucas, A., Cabrales, P., and Palmer, A. F. (2020). Tumor Vascular Status Controls Oxygen Delivery Facilitated by Infused Polymerized Hemoglobin with Varying Oxygen Affinity. *Plos Comput. Biol.* 16, e1008157. doi:10.1371/journal.pcbi.1008157

Bhattacharjee, R. N., Patel, S. V. B., Sun, Q., Jiang, L., Richard-Mohamed, M., Rotherkanthan, A., et al. (2020). Renal Protection against Ischemia Reperfusion Injury: Hemoglobin-Based Oxygen Carrier-201 versus Blood as an Oxygen Carrier in Ex Vivo Subnormothermic Machine Perfusion. *Transplantation* 104, 482–489. doi:10.1097/TP.0000000000002967

Bleeker, W. K., van der Plas, J., Feitsma, R. L., Ag terberg, J., Rijger, G., de Vries-van Rossen, A., et al. (1989). In Vivo distribution and Elimination of Hemoglobin Modified by Intramolecular Cross-Linking with 2-Nor-2-Formylpyridoxal 5'-phosphate. *J. Lab. Clin. Med.* 113, 151–161.

Bobofchak, K. M., Mito, T., Texel, S. J., Bellelli, A., Nemoto, M., Trasymann, R. J., et al. (2003). A Recombinant Polymeric Hemoglobin with Conformational, Functional, and Physiological Characteristics of an In Vivo O2 Transporter. *Am. J. Physiol. Heart Circ. Physiol.* 285, H549–H561. doi:10.1152/ajpheart.00372003

Boteon, Y. L., Laing, R. W., Schlegel, A., Wallace, L., Smith, A., Attard, J., et al. (2019). The Impact on the Bioenergetic Status and Oxidative-Mediated Tissue Injury of a Combined Protocol of Hypothermic and Normothermic Machine Perfusion Using an Acellular Haemoglobin-Based Oxygen Carrier: The Cold-To-Warm Machine Perfusion of the Liver. *PLOS One* 14, e0224066. doi:10.1371/journal.pone.0224066

Cabrales, P., Sun, G., Zhou, Y., Harris, D. R., Tsai, A. G., Intaglia 17. et al. (2009). Effects of the Molecular Mass of Tense-State Polymerized Bovine Hemoglobin on Blood Pressure and Vasconstriction. *J. Appl. Physiol.* 107, 1548–1558. doi:10.1152/japplphysiol.00622.2009

Cai, Y., Dai, Z., Wen, S., and Bhandari, R. (2020). Risk Factors Associated with Infection of Blood-Borne Virus Among People Who Used Methamphetamine. *BMC Infect. Dis.* 20, 742. doi:10.1186/s12879-020-05464-y

Callas, D. D., Clark, T. L., Moreira, P. L., Lansden, C., Gawryl, M. S., Kahn, S., et al. (1997). In *Vitro* effects of a Novel Hemoglobin-Based Oxygen Carrier on Routine Chemistry, Therapeutic Drug, Coagulation, Hematology, and Blood Bank Assays. *Clin. Chem.* 43, 1744–1748. doi:10.1093/clinchem/hvg1744

Carlsson, P. O., and Palm, F. (2002). Oxygen Tension in Isolated Transplanted Rat Islets and in Islets of Whole Pancreas Transplants. *Transpl. Int.* 15, 581–585. doi:10.1007/s00114-002-0460-7

Caswell, J. E., Strange, M. B., Rimmer, D. M., 3rd, Gibson, M. F., Cole, P., and Lefer, D. J. (2005). A Novel Hemoglobin-Based Blood Substitute Protects against Myocardial Reperfusion Injury. *Am. J. Physiol. Heart Circ. Physiol.* 288, H1796–H1801. doi:10.1152/ajpheart.00905.2004

Dame, S. S., Moore, E. B., Babu, A. N., Meng, X., Fullerton, D. A., and Banerjee, A. (2009). Hemoglobin-based Oxygen Carrier Induces Heme Oxygenase-1 in the Heart and Lung but Not Brain. *J. Am. Coll. Surg.* 208, 592–598. doi:10.1016/j.jamcollsurg.2009.01.015

Cao et al.
HBOCs: Applications in Organ Preservation

Dixit, V. A., Blumberger, J., and Vyas, S. K. (2021). Methemoglobin Formation in

Baltzer, A. P. M., Nijsten, M. W. N., Werner, M. J. M., van den Berg, A.

Cao et al. HBOCs: Applications in Organ Preservation

Dixit, V. A., Blumberger, J., and Vyas, S. K. (2021). Methemoglobin Formation in

Baltzer, A. P. M., Nijsten, M. W. N., Werner, M. J. M., van den Berg, A.

Cao et al. HBOCs: Applications in Organ Preservation

Dixit, V. A., Blumberger, J., and Vyas, S. K. (2021). Methemoglobin Formation in
Cao et al. HBOCs: Applications in Organ Preservation

Page, T. C., Light, W. R., McKay, C. B., and Hellums, J. D. (1998). Oxygen Transport by Erythrocyte/hemoglobin Solution Mixtures in an In Vitro Capillary as a Model of Hemoglobin-Based Oxygen Carrier Performance. Microvasc. Res. 55, 54–64. doi:10.1006/mvre.1997.2015

Partlow, K. C., Lanza, G. M., and Wickline, S. A. (2008). Exploiting Lipid Raft Transport with Membrane Targeted Nanoparticles: a Strategy for Cytosolic Drug Delivery. Biomaterials 29, 3367–3375. doi:10.1016/j.biomaterials.2008.04.030

Pearce, L. B., and Gawryl, M. S. (2003). The Pharmacology of Tissue Oxygenation by Biopure’s Hemoglobin-Based Oxygen Carrier, Hemopure (HBOC-201). Adv. Exp. Med. Biol. 530, 261–270. doi:10.1007/978-1-4615-0075-9_25

Reitz, B. A., Gaudiani, V. A., Hutter, S. A., Wallwork, J., Billingham, M. E., Oyer, P. E., et al. (1983). Diagnosis and Treatment of Allograft Rejection in Heart-Lung Transplant Recipients. J. Thorac. Cardiovasc. Surg. 85, 354–361. doi:10.1016/s0022-5197(19)37565-8

Rother, R. P., Bell, L., Hillmen, P., and Gladwin, M. T. (2005). The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin: a Novel Mechanism of Human Disease. JAMA 293, 1653–1662. doi:10.1001/jama.293.13.1653

Roussetol, M., Delpy, E., Drieu La Rochelle, C., Lagente, V., Pirow, R., Rees, J. F., et al. (2006). Arenaluna marina Extracellular Hemoglobin: a New Promising Blood Substitute. Biotechnol. J. 1, 333–345. doi:10.1002/biot.200500049

Sahu, S. C., Simplanon, Y., Gong, Q., Ho, N. T., Glishka, J. G., Prestage, J. H., et al. (2006). Orientation of Deoxyhemoglobin at High Magnetic Field: Structural Insights from RDCs in Solution. J. Am. Chem. Soc. 128, 6291–6291. doi:10.1021/ja060023z

Sakai, H., Hamada, K., Takeoka, S., Nishide, H., and Tsuda, E. (1996). Physical Properties of Hemoglobin Vesicles as Red Cell Substitutes. Biotechnol. Prog. 12, 119–125. doi:10.1021/bp950068w

Sakai, H., Horinouchi, H., Tomiyama, K., Ikeda, E., Takeoka, S., Kobayashi, K., et al. (2001). Hemoglobin-vesicles as Oxygen Carriers: Influence on Phagocytic Activity and Histopathological Changes in Rectaladenothelial System. Am. J. Pathol. 159, 1079–1088. doi:10.1016/S0002-7414(10)61783-X

Sakai, H., Tomiyama, K. L., Sou, K., Takeoka, S., and Tsuda, E. (2000). Poly(ethylene Glycol)-Conjugation and Deoxygenation Enable Long-Term Preservation of Hemoglobin-Vesicles as Oxygen Carriers in a Liquid State. Bioconjug. Chem. 11, 425–432. doi:10.1021/bc990173h

Sakai, T., Li, S., Kudoya, Y., Tanioka, Y., Fujino, Y., and Suzuki, Y. (2011). Oxygenation of the portal Vein by Intraportal Administration of Oxygenated Perfluorochemical Improves the Engraftment and Function of Intraportally Transplanted Islets. Pancreas 40, 403–409. doi:10.1097/MPA.0b013e318204e815

Sarani, B., and Gracias, V. (2008). Hemoglobin-based Blood Substitutes and Risk of Myocardial Infarction and Death. JAMA 300, 1297–1299. doi:10.1001/jama.300.11.1297-b

Sauaia, A., Moore, E. E., and Banerjee, A. (2008). Hemoglobin-based Blood Substitutes and Risk of Myocardial Infarction and Death. JAMA 300, 1297–1299. doi:10.1001/jama.300.11.1297-a

Scatena, R., and Giardina, B. (2001). O-rasino-polymserised Haemoglobin. A Biochemical and Pharmacological Profile of an Oxygen Carrier. Expert Opin. Biol. Ther. 1, 121–127. doi:10.1517/147122598.1.121

Shonaka, T., Matsuno, N., Obara, H., Yoshikawa, R., Nishikawa, Y., Gouchi, M., et al. (2018). Application of Perfusion with Human-Derived Oxygen Carrier Solution under Subnormothermic Machine Perfusion for Donation after Cardiac Death Liver Grafts in Pigs. Transpl. Proc. 50, 2821–2825. doi:10.1016/j.transproceed.2018.02.184

Shonaka, T., Matsuno, N., Obara, H., Yoshikawa, R., Nishikawa, Y., Ishihara, Y., et al. (2019). Impact of Human-Derived Hemoglobin Based Oxygen Vesicles as a Machine Perfusion Solution for Liver Donation after Cardiac Death in a Pig Model. PloS one 14, e0226183. doi:10.1371/journal.pone.0226183

Simoni, J., Simoni, G., Hartsell, A., and Feola, M. (1997). An Improved Blood Substitute. In Vivo Evaluation of its Retinal Effects. ASAIO J. 43, M714–M725. American Society for Artificial Internal Organs : 1992. doi:10.1097/0002840–199703000–00046

Standl, T. (2005). A New Oxygen Transport Agent. Haematologica 90, 437–438. doi:10.3324%2525%20

Standl, T., Freitag, M., Burmeister, M. A., Horn, E. P., Wilhelm, S., and Am Esch, J. S. (2003). Hemoglobin-based Oxygen Carrier HBOC-201 Provides Higher
and Faster Increase in Oxygen Tension in Skeletal Muscle of Anemic Dogs Than Stored Red Blood Cells. *J. Vasc. Surg.* 37, 859–865. doi:10.1067/mva.2003.127

Taverne, Y. J., de Wijs-Meijler, D. T., Leint Lekert, M., Moon-Massat, P. F., Dubé, G. P., Duncker, D. L., et al. (2017). Normalization of Hemoglobin-Based Oxygen Carrier-201 Induced Vasoonstriction: Targeting Nitric Oxide and Endothelin. *J. Appl. Physiol.* 122, 1227–1237. doi:10.1152/japplphysiol.00677.2016

Teh, E. S., Zal, F., Polard, V., Menasché, P., and Chambers, D. J. (2017). HEMO2life as a Protective Additive to Celsior Solution for Static Storage of Donor Hearts Prior to Transplantation. *Artif. Cell Nanomed Biotechnol* 45, 717–722. doi:10.1080/21691401.2016.1265974

Thuillier, R., Dutheil, D., Trieu, M. T., Mallet, V., Allain, G., Rousselot, M., et al. (2011). Supplementation with a New Therapeutic Oxygen Carrier Reduces Chronic Fibrosis and Organ Dysfunction in Kidney Static Preservation. *Am. J. Transpl.* 11, 1845–1860. doi:10.1111/j.1600-6143.2011.03614.x

Tian, T., Lindell, S. L., Henderson, S. C., and Mangino, M. J. (2009). Protective Effects of Ezrin on Cold Storage Preservation Injury in the Pig Kidney Proximal Tubular Epithelial Cell Line (LLC-PK1). *Transplantation* 87, 1488–1496. doi:10.1097/TP.0b013e3181a43f18

Topp, S. A., Krieg, A., Koch, A., Tiddem, C. M., Ramp, U., Hohlfeld, T., et al. (2008). Hemoglobin-glutamer 200 Reduces Reperfusion Injury of the Cold Preserved Rat Liver by Induction of Heme Oxygenase-1. *J. Surg. Res.* 150, 243–254. doi:10.1016/j.jsrs.2008.02.033

Toulmond, A., Slitine, F. E. L., De Frescheville, J., and Jouin, C. (1996). Extracapillar Hemoglobinins of Hydrothermal Vent Annelids: Structural and Functional Characteristics in Three Alvinellid Species. *Biol. Bull.* 179, 366–373. doi:10.2307/1542329

Tran, N. Q., Malcontenti-Wilson, C., Hammoud, S., Millar, I., Christopher, C., and Muralidharan, V. (2012). Hyperbaric Oxygen Therapy Reduces the Severity of Ischaemia, Preservation and Reperfusion Injury in a Rat Model of Liver Transplantation. *HPB (Oxford)* 14, 103–114. doi:10.1111/j.1477-2574.2011.00410.x

Tsujimura, T., Kuroda, Y., Kin, T., Avila, J. G., Rajotte, R. V., Korbutt, G. S., et al. (2011). Extracapillar Hemoglobinins of Hydrothermal Vent Annelids: Structural and Functional Characteristics in Three Alvinellid Species. *Biol. Bull.* 179, 366–373. doi:10.2307/1542329

Unnikrishnan, A., Pelletier, J. P. R., Bari, S., Zumberg, M., Shahmohamadi, A., Spiess, B. D., et al. (2019). Anti-N and Anti-Do immunoglobulinGalloantibody-mediateddelayed Hemolytic Transfusion Reaction with Hyperhemolysis in Sickle Cell Disease Treated with Eculizumab and HBOC -201:case Report and Review of the Literature. *Transfus.* 59, 1907–1910. doi:10.1111/trf.15198

van Leeuwen, O. B., de Vries, Y., Fujiiyoshi, M., Nijsten, M. W. N., Ubbink, R., Pelgrim, G. J., et al. (2019). Transplantation of High-Risk Donor Livers after Ex Situ Resuscitation and Assessment Using Combined Hypo- and Normothermic Machine Perfusion: A Prospective Clinical Trial. *Ann. Surg.* 270, 906–914. doi:10.1097/SLA.0000000000003540

Warnecke, G., Strüber, M., Hohlfeld, J. M., Niedermeyer, J., Sommer, S. P., and Haverich, A. (2002). Pulmonary Preservation with Bretschneider’s HTK and Celsior Solution in Minipigs. *Eur. J. cardio-thoracic Surg.* : of official J. Eur. Assoc. Cardio-thoracic Surg. 21, 1073–1079. doi:10.1016/s1010-7940(02)00106-9

Wei, L., Wu, R. B., Yang, C. M., Zheng, S. Y., and Yu, X. Y. (2011). Cardioprotective Effect of a Hemoglobin-Based Oxygen Carrier on Cold Ischemia/reperfusion Injury. *Cardiology* 120, 73–83. doi:10.1159/000333106

White, C. W., Hashanally, D., Mundt, P., Li, Y., Xiang, B., Klein, J., et al. (2015). A Whole Blood-Based Per fusate Provides Superior Preservation of Myocardial Function during Ex Vivo Heart Perfusion. *J. Heart Lung Transplant.* : of official Publ. Int. Soc. Heart Transplant. 34, 113–121. doi:10.1016/j.healun.2014.09.021

York, G. B., DiGeronimo, R. J., Wilson, B. J., Cofer, R. B., Breuer, C. K., Josephs, J. D., et al. (2002). Extracorporeal Membrane Oxygenation in Piglets Using a Polymerized Bovine Hemoglobin-Based Oxygen-Carrying Solution (HBOC-201). *J. Pediatr. Surg.* 37, 1387–1392. doi:10.1053/jpsu.2002.35374

Yoshida, H., Okuno, H., Kamoto, T., Habuchi, T., Toda, Y., Hasegawa, S., et al. (2002). Comparison of the Effectiveness of ET-Kyoto with Euro-Collins and University of Wisconsin Solutions in Cold Renal Storage. *Transplantation* 74, 1231–1236. doi:10.1097/00007890-200211150-00006

You, Z., Li, T., Yang, C., Wu, H., Peng, X., Zeng, Y., et al. (2011). Comparison of the Cardioprotective Effect of Deoxygeng Hemoglobin-based Oxygen Carrier (HBOC) Pretreatment and Ischemia Preconditioning. *Artif. Cells Blood Substit. Immobil. Biotechnol.* 39 (1), 7–11. doi:10.3109/10731199.2010.495037

Zal, F., Green, B. N., Lallier, F. H., Vinogradov, S. N., and Toulmond, A. (1997). Quaternary Structure of the Extracapillary Haemoglobin of the Lugworm Arenicola marina: a Multi-Angle-Laser-Light-Scattering and Electrospray-Ionisation-Mass-Spectrometry Analysis. *Eur. J. Biochem.* 243, 85–92. doi:10.1111/j.1432-1033.1997.85_1a.x

Zhu, Y., Zhang, J., Wu, Y., Tian, K., Peng, X., Xiang, J., et al. (2019). Beneficial Effects of Hemoglobin-Based Oxygen Carriers on Early Resuscitation in Rats with Uncontrolled Hemorrhagic Shock. *Zhonghua Wei Zhong Bing Ji Jiu Xue* 31, 81–86. doi:10.3760/cma.j.issn.2095-4532.2019.01.016

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Cao, Wang, He, Yue, Zhao, Pan, Huang, Guo, Yin, Ma, Zhang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
GLOSSARY

SOT  solid organ transplantation
DCD  donation after cardiac death
IRI  ischemia–reperfusion injury
ECD  expanded criteria donor
SCS  static cold storage
ATP  adenosine triphosphate
RBCs  red blood cells
RBC  red blood cell
PFCs  perfluorochemicals
SNMP  subnormothermic machine perfusion
NMP  normothermic machine perfusion
HBOCs  hemoglobin-based oxygen carriers
Hb  hemoglobin
Mb  myoglobin
MI  myocardial infarction
FDA  Food and Drug Administration
EA  expanded access
ECMO  extracorporeal membrane oxygenation
HbV  hemoglobin-vesicles
PolyPHb  polymerized human placenta hemoglobin
HbG  hemoglobin glutamer
PLP  pyridoxal phosphate
GDA  glutaraldehyde
PEG  polyethylene glycol
NO  nitric oxide
ET  endothelin
CO  carbon monoxide
EC  Euro-Collins
UW  University of Wisconsin
HTK  histidine–tryptophan–ketoglutarate
DHOPE  dual hypothermic oxygenated machine perfusion
COR  controlled oxygenated rewarming

MP  machine perfusion
TLR2  toll-like receptor 2
TLR4  toll-like receptor 4
NF-kB  nuclear factor kappa B
LVDP  left ventricular development pressure
EVHP  ex vivo heart perfusion
ROS  reactive oxygen species
CVR  coronary vascular resistance
GMP  good manufacturing practice
SOD  superoxide dismutase
MDA  malondialdehyde
PGD  primary graft dysfunction
BALF  bronchoalveolar lavage fluid
PaO2/FiO2  arterial partial pressure of oxygen to fraction of inspired oxygen ratio
HMGB1  high mobility group box 1
RAGE  advanced glycation end products
EVLP  ex vivo lung perfusion
HO-1  heme oxygenase 1
SnPP  Tin protoporphyrin IX dichloride
CS  cold storage
Mrp2  multidrug resistance–associated protein 2
Bsep  bile salt export pump
JNK  c-Jun N-terminal kinase
HOPE  hypothermic oxygenated machine perfusion
CSP  current standard-of-care
HMP  hypothermic machine perfusion
IFTA  interstitial fibrosis and tubular atrophy
NGLA  neutrophil gelatinase–associated lipocalin
KIM-1  kidney injury molecule-1
PRBC  packed red blood cell
PolyHb  polyhemoglobin
HCA  hypertonic adenine citrate solution